Associations - ALK wild-type

ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1	nivolumab Sensitive: A1 - Approval nivolumab Sensitive : A1
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B	durvalumab + tremelimumab-actl Sensitive: B - Late Trials durvalumab + tremelimumab-actl Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B	durvalumab Sensitive: B - Late Trials durvalumab Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B	toripalimab-tpzi Sensitive: B - Late Trials toripalimab-tpzi Sensitive : B
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ALK wild-type	Lung Non-Small Cell Squamous Cancer	ALK wild-type	Lung Non-Small Cell Squamous Cancer	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B	cemiplimab-rwlc Sensitive: B - Late Trials cemiplimab-rwlc Sensitive : B
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B	atezolizumab Sensitive: B - Late Trials atezolizumab Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B	nivolumab + ipilimumab Sensitive: B - Late Trials nivolumab + ipilimumab Sensitive : B
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B	nivolumab + bevacizumab Sensitive: B - Late Trials nivolumab + bevacizumab Sensitive : B
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2	anlotinib + sintilimab Sensitive: C2 – Inclusion Criteria anlotinib + sintilimab Sensitive : C2
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3	ivonescimab Sensitive: C3 – Early Trials ivonescimab Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3	atezolizumab Sensitive: C3 – Early Trials atezolizumab Sensitive : C3
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3	sintilimab Sensitive: C3 – Early Trials sintilimab Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3	tislelizumab-jsgr Sensitive: C3 – Early Trials tislelizumab-jsgr Sensitive : C3
ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	ALK wild-type	Lung Non-Squamous Non-Small Cell Cancer	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3	pucotenlimab Sensitive: C3 – Early Trials pucotenlimab Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3
ALK wild-type	Lung Cancer	ALK wild-type	Lung Cancer	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D	crizotinib Sensitive: D – Preclinical crizotinib Sensitive : D

Full access to predictive biomarker details and heatmap analytics are available with a VERI Account.